Compare Illumina, Inc. (ILMN) vs IONQ Inc (IONQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs IONQ Inc — how do they compare? Illumina, Inc. trades at $191.75 (market cap $29.12B), while IONQ Inc trades at $45.01 (market cap $17.60B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Illumina, Inc. is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | IONQ | |
|---|---|---|
Market Cap | $29.12B | $17.60B |
Sector | Health | Technology |
52-Week High | $205.10 | $82.09 |
52-Week Low | $91.00 | $26.59 |
Enterprise Value | $30.48B | $15.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $191.32, down 0.25% on the day, with a bullish earnings trend after beating Q2 2026 estimates. The stock shows strong profitability with a net margin of 18.34% and positive cash flow, though technical indicators signal near-term bearish pressure. Recent news highlights institutional buying and AI partnerships boosting growth prospects.
Outlook remains positive with a consensus price target of $201.58, offering ~5% upside, supported by solid fundamentals and analyst optimism. Risks include high valuation multiples and competitive pressures in genomics. The stock presents a growth opportunity with manageable near-term volatility.
IONQ trades at $44.82, up 5.38% with a bullish technical signal supported by moving averages. The quantum computing company reported explosive 287% revenue growth in Q2 2026 to $80.1 million and raised its full-year outlook, though it remains deeply unprofitable with a -553% net margin. Recent catalysts include a $28 million DARPA contract extension and strong analyst sentiment with a $73.33 consensus price target representing 64% upside potential.
While IONQ demonstrates exceptional revenue momentum and technological leadership in quantum computing, investors face substantial risk from persistent losses, high cash burn, and valuation multiples exceeding 60x sales. The stock offers significant growth potential but requires tolerance for volatility and a long-term horizon given the nascent stage of quantum commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →
